Viewing nowLobaga 20 mg (Rosuvastatin Calcium)
Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Ari Pharmaceutical Co., Ltd.

MFDS item code 201906848 · Approved 2019.09.26 · Insurance code 058200240
Improvement of dyslipidemia; inhibition of the progression of atherosclerosis; prevention of cardiovascular disease
This medication is used as an adjunct to diet for patients with primary hypercholesterolemia and mixed dyslipidemia when these conditions cannot be controlled by diet and exercise alone. It can also be administered as an adjunct to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. This drug effectively lowers total cholesterol and LDL cholesterol to target levels in patients with hypercholesterolemia, helping to delay the progression of atherosclerosis. It is also used as an adjunct to dietary therapy in patients with primary dysbetalipoproteinemia. It assists in reducing the risk of myocardial infarction, stroke, and artery revascularization in men over 50 years and women over 60 years with elevated high-sensitivity C-reactive protein levels beyond certain thresholds. Therefore, this medication is effectively used to improve hyperlipidemia and the risk of cardiovascular diseases.
1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine should follow a standard cholesterol-lowering diet before and during treatment, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: Dose adjustment is not necessary. 3. Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
This medication should not be used by individuals who are allergic to any of its components. Patients with active liver disease or abnormally high liver enzyme levels should also avoid this medication. Women who are pregnant or nursing should not use this drug. Patients at high risk for muscle disorders, particularly those on high doses, should exercise caution as there are several risk factors involved. Patients with lactose intolerance or specific genetic metabolic disorders should not take this medication. This drug may affect liver function, so those with a history of liver disease or high alcohol consumption should use caution. Muscle-related side effects such as myalgia, myopathy, and rarely, rhabdomyolysis can occur, and any symptoms should be reported to healthcare professionals immediately. Muscle enzyme levels should be tested before and during treatment, and if abnormalities are noted, dosing should be adjusted or discontinued. In cases of acute severe conditions or serious physical illnesses, use should be discontinued. Rarely, this drug can cause severe skin reactions or liver damage, so if symptoms such as skin rash or jaundice appear, treatment should be stopped immediately. There may be interactions with other medications, so it is crucial to inform healthcare providers about any other medications being taken. Particularly, caution is warranted when co-administering drugs that may increase the risk of muscle toxicity. Pregnant or nursing women should not use this medication, and women of childbearing potential should use appropriate contraception. In case of overdose, no specific antidote exists, hence treatment should be symptomatic with monitoring of liver function and muscle enzymes. Caution is advisable when driving or operating machinery as dizziness may occur.
Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, dysesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius.
Pink round film-coated tablets
PE bottle packaging - 30 tablets/bottle, PE bottle packaging - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Ari Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.